GLP-1 Medicines for Teens: 20 Questions Families Can Ask

Yes, some GLP-1 medicines are FDA-approved for teenagers, but only certain products, for certain conditions and ages. Wegovy (semaglutide) and Saxenda (liraglutide) are labeled for weight management in adolescents 12 and older who meet the label's criteria, and the American Academy of Pediatrics (AAP) says pediatricians should offer weight-loss medication to adolescents 12 and older with obesity, alongside lifestyle treatment.

That is the short answer. The longer one is a family conversation, and it goes better when you walk in with good questions. This guide gives you the facts from the labels and trials, plus 20 questions to bring to the pediatrician, sorted by topic.

Which GLP-1 medicines are approved for teens?

Labels are specific, and the differences matter. Here is what each current US label says in its pediatric use section:

Medicine	Pediatric labeling (US)
Wegovy (semaglutide injection)	Weight reduction and long-term maintenance in patients 12 and older with obesity (BMI at or above the 95th percentile for age and sex)
Saxenda (liraglutide)	Weight management in patients 12 and older with body weight above 60 kg and a BMI matching adult obesity by international cut-offs
Mounjaro (tirzepatide)	Blood sugar control in type 2 diabetes, 10 and older; not established under 10
Victoza (liraglutide), Trulicity (dulaglutide)	Blood sugar control in type 2 diabetes, 10 and older
Zepbound (tirzepatide)	"Safety and effectiveness... have not been established in pediatric patients"
Ozempic (semaglutide)	Not established in pediatric patients

Two things jump out. First, the same molecule can be approved for teens under one brand and not another (tirzepatide is labeled for teens with type 2 diabetes as Mounjaro, but Zepbound has no pediatric indication). Second, the type 2 diabetes approvals are about blood sugar, not weight. If a clinician suggests a product outside its labeled age or use, that is off-label prescribing, which is legal but worth asking about.

Tirzepatide trials in teens with obesity, such as SURMOUNT-ADOLESCENTS (160 teens enrolled, listed as active but no longer recruiting), are registered on ClinicalTrials.gov, but a trial is not an approval.

What did the teen trial actually show?

The main study behind Wegovy's teen approval is STEP TEENS, published in the New England Journal of Medicine in 2022. Here is the plain version:

• Who: 201 adolescents aged 12 to under 18, almost all with obesity.
• What: Weekly semaglutide 2.4 mg or placebo for 68 weeks, both groups with a lifestyle program.
• Result: Average BMI dropped 16.1% with semaglutide and rose 0.6% with placebo. 73% of the semaglutide group lost at least 5% of their weight, vs 18% on placebo.
• Side effects: Stomach and gut side effects in 62% vs 42%. Gallstones in 5 teens (4%) on semaglutide and none on placebo. Serious adverse events in 11% vs 9%.
• Funding: Novo Nordisk, which makes Wegovy.

The Wegovy label adds that teens in the trial had higher rates of gallstones, gallbladder inflammation, low blood pressure, rash and hives than adults did. The Saxenda label notes, from its 251-teen trial, one case of pancreatitis, more low-blood-sugar episodes than placebo, and resting heart rate increases of 3 to 7 beats per minute.

What do pediatricians' guidelines say?

The AAP published its first clinical practice guideline on child and adolescent obesity in 2023. According to the AAP's own summary:

• Physicians should offer adolescents 12 and older with obesity weight-loss medication, as an add-on to lifestyle treatment, based on each drug's indications, risks and benefits.
• The most effective behavioral treatment is 26 or more hours of face-to-face, family-based treatment over 3 to 12 months. The AAP admits this is hard to find.
• Teens 13 and older with severe obesity should be evaluated for metabolic and bariatric surgery.
• Stigma is harmful, and evidence-based treatment by trained professionals can result in less disordered eating, not more.

What is still unknown?

Plenty, and good clinicians will say so. A 2024 Pediatrics paper from an NIH (NIDDK) workshop noted a limited evidence base to guide these decisions and limited data on long-term safety during growth and development. Trials last about a year or so; teens may need treatment much longer. Questions about growth, puberty, bone health, and what happens when medicine is stopped are still being studied. For adults, weight tends to come back after stopping semaglutide (here's what that research found), and families should ask what the plan would be.

One update worth knowing: in January 2026 the FDA asked makers of Saxenda, Wegovy and Zepbound to remove the suicidal thoughts and behavior warning from their labels after a review of 91 placebo-controlled trials found no increased risk. The FDA still says to tell the prescriber about new or worsening depression or unusual mood changes, and anyone in crisis can call or text 988.

20 questions families can ask the pediatrician

Print these, pick the ones that matter, and let your teen add their own.

About the "why"

1. What exactly would this medicine treat: obesity, type 2 diabetes, or another condition?
2. Is this product FDA-approved for my teen's age and condition, or would it be off-label?
3. What other options come first or alongside, and are family-based programs available near us?
4. What health problems are you hoping to improve, beyond the number on the scale?

About the medicine itself

5. How is it given (weekly shot, daily shot), and who will do the injections?
6. How does the dose increase over the first months, and what side effects are common during that time?
7. Which symptoms mean call you, and which mean urgent care? (Stomach pain that won't go away and gallbladder symptoms are on the labels.)
8. Does it interact with any of my teen's other medicines, including acne, ADHD or birth control?
9. If my teen has diabetes or uses insulin, how do we watch for low blood sugar?

About growth, body and mind

10. How will you check growth, puberty and nutrition while on treatment?
11. How do we make sure they're getting enough protein and nutrients when appetite drops?
12. How will you screen for disordered eating before and during treatment? (See our post on eating-disorder history and GLP-1s.)
13. Who do we call if mood, sleep or school performance changes?
14. Does it affect sports or exercise?

About the long run

15. How long would treatment likely last, and how will we decide if it's working?
16. What happens if we stop, and how would we stop?
17. What will insurance cover, and what happens if coverage changes?
18. How often are follow-up visits, and who on the team do we contact between them?

About the teen

19. Can my teen talk with you alone for part of the visit?
20. What would you want my teen to understand that I might not think to ask?

You can adapt our adult starter questions too, though some won't apply.

How to talk about it at home without shame

A few tips from the spirit of the AAP guidance, and from common sense:

• Talk about health and energy, not looks. "How do you feel playing soccer?" beats any comment about size.
• Make it their decision as much as possible. Teens follow plans they helped build.
• Keep it private if they want. It's their health information. They decide who knows, including siblings and grandparents. Our guide to GLP-1 stigma has scripts for nosy questions.
• Change the household, not just the kid. Family-based treatment works best when everyone eats the same food and moves together.
• Skip before-and-after comparisons. Influencer timelines are adult stories, often on different products.

Common questions

Is Wegovy approved for teenagers?

Yes. The Wegovy injection label covers weight reduction and long-term maintenance in patients 12 and older with obesity, defined as a BMI at or above the 95th percentile for age and sex, used with a reduced-calorie diet and more physical activity.

Can a 14-year-old take Zepbound?

The Zepbound label says safety and effectiveness have not been established in pediatric patients. Tirzepatide is labeled for teens 10 and older with type 2 diabetes under the brand Mounjaro, and teen obesity trials are ongoing.

Does the AAP recommend weight-loss drugs for kids?

The AAP's 2023 guideline says pediatricians should offer weight-loss medication to adolescents 12 and older with obesity, as an add-on to health behavior and lifestyle treatment, based on each medicine's indications, risks and benefits. It does not set a blanket rule for younger children.

Will my teen gain the weight back if they stop?

Long-term data in teens are limited. In adults, weight tends to return after stopping semaglutide. Ask the pediatrician what the plan would be before starting.